Efalizumab-induced autoimmune pancytopenia

British Journal of Dermatology

Volumn 155, Issue 5, 2006, Pages 1045-1047

  Tom, W L ^a   Miller, M D ^a   Hurley, M Y ^a   Suneja, T ^a   Kudva, G ^a   Leonardi, C L ^a   Obadiah, J M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; Efalizumab; Pancytopenia

Indexed keywords

EFALIZUMAB; HAPTOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RECOMBINANT ANTIBODY;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; CASE REPORT; CHILL; DRUG INDUCED DISEASE; DRUG RESPONSE; ECCHYMOSIS; FATIGUE; FEMALE; FEVER; HEMOLYSIS; HUMAN; IMMUNE MEDIATED INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; MYALGIA; NEUTROPENIA; PANCYTOPENIA; PATIENT MONITORING; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; SIDE EFFECT; SORE THROAT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; AUTOIMMUNE DISEASES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; PANCYTOPENIA; PSORIASIS;

EID: 33749826860     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07437.x     Document Type: Article

References (12)

1. Sauder DN, Mamelak AJ. Understanding the new clinical landscape for psoriasis: a comparative review of biologics. J Cutan Med Surg 2004; 8:205-12.
2. Cather JC, Menter A. Efalizumab: continuous therapy for chronic psoriasis. Expert Opin Biol Ther 2005; 5:393-403.
3. Jordan JK. Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother 2005; 39:1476-82.
4. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64 (Suppl. 2): ii87-92.
5. Package insert. Raptiva (efalizumab). San Francisco: Genentech, 2005.
6. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352:1899-912.
7. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425-33.
8. Aster RH. Drug-induced immune cytopenias. Toxicology 2005;209:149-53.
9. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004; 27:1243-52.
10. Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005; 23:247-50.
11. Kuruvilla J, Leitch HA, Vickars LM et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003; 71:396-8.
12. Philippeaux MM, Vesin C, Tacchini-Cottier F, Piguet PF. Activated human platelets express beta2 integrin. Eur J Haematol 1996;56:130-7.